Compounded Tesamorelin / Ipamorelin

No. A consultation does not guarantee a prescription. A licensed provider reviews your history at the visit and decides whether this is appropriate for you; because the substance is not on FDA's list for compounding and the human data is thin, many providers will reasonably decline. If they decline, the medication portion of what you paid is refunded automatically; the consultation fee is not.

No. Compounded drugs are not FDA-approved. Tesamorelin on its own is the active ingredient of Egrifta, which is approved for one narrow use in HIV lipodystrophy; ipamorelin is not the active ingredient of any approved product, and FDA's committee voted against allowing it in compounding. This combination has never been reviewed by FDA for safety, effectiveness or quality.

Yes. Its regulatory status can change at any time: FDA's advisory committee vote is a recommendation, FDA's own rulemaking decides the list, a state pharmacy board can act on its own, and our partner pharmacy can stop preparing it. If any of that happens we stop offering it, tell you, and refund the medication portion of any order the pharmacy can no longer fill.

No. Its approved use is reducing excess abdominal fat in adults with HIV-associated lipodystrophy, and the label says in plain words that it is not indicated for weight-loss management. If weight is your goal, the Weight Loss section holds the medications with trial evidence for it; this is not a substitute.

Because ipamorelin has no lawful basis for compounding at all — FDA's committee voted 0 to 12 against it in October 2024 — and a mixture is only as listable as its least-listable ingredient. Tesamorelin by itself rests on the approved product's active ingredient; the pair rests on nothing until FDA's rulemaking says otherwise.